EN DE
Watch Charles River Laboratories for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Charles River Laboratories (CRL) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Charles River Laboratories stock $121, price $313, that is 61.5% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CR Charles River Laboratories logo Some data Nov 6, 2026

Charles River Laboratories

CRL · US
Solid, but very expensive

Our calculation puts a fair price 61% below what the stock costs today.

Quality 60/100
Generates free cash flow
Positive coverage
Mixed Growth (revenue 5y +6.5 %/yr in USD)
Thin margins · 1.0% net margin (TTM) · excl. goodwill write-downs +5.2%
Moderate debt
Insiders sold $52.1M (6M)
Some data
Fair value $120.66 · Strongly overvalued (−61.5%)
Trails peers (3/14)
Narrow moat 42/100
Watch Charles River Laboratories for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$458.30 $99.75 Fair Value $120.66 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $99.75 – $458.30 · fair‑value band $75.61 – $165.70 · the $313.02 price screens above the $120.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Charles River Laboratories in your weekly email

Every Wednesday you see whether Charles River Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

Show moreShow less

The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.

This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.

The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.

The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services.

The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization.

Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Stock analysis

Charles River Laboratories (CRL) currently trades at $313.02, while our model-based Fair Value estimate is $120.66, 61% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $142.18 per share, and 0 of the 14 models we run sit above the $313.02 price.

Bear case: the Earnings-Based group reads lowest at $55.68, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $75.61 (bear) to $165.70 (bull), the price of $313.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Charles River Laboratories reported revenue of $4.0B in FY2025 versus $3.5B in FY2021, a compound +3.2%/yr. Reported net income was −$144M in FY2025.

Key figures

Market cap $15.2B Large · P/E ratio 340.2 · P/S ratio 3.82 · EPS (TTM) $0.9200 · Net margin 1.0% · Return on equity 1.3% · Return on assets (EBIT) 6.9% · Operating margin 20.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 17% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −61%, CRL screens richer than that median.

Fair Value models

Bear $75.61 Fair Value $120.66 Bull $165.70
Price $313.02 · Downside -61.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.7814 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $102.03 $190.92 $326.91 77
Growth DCF $101.67 $184.22 $306.02 76
EPV $43.26 $55.68 $66.26 74
All 14 models by family
DCF Models
FCF DCF $102.03 $190.92 $326.91 77
Owner Earnings n/a $16.72 $49.95 73
5Y Revenue Exit $71.07 $137.79 $224.63 70
5Y EBITDA Exit $126.94 $248.42 $396.30 73
10Y Revenue Exit $78.25 $142.18 $232.62 65
10Y EBITDA Exit $115.95 $217.88 $364.66 66
Earnings-Based
EPV $43.26 $55.68 $66.26 74
Multiples
EV/EBIT $75.61 $120.66 $165.70 64
EV/EBITDA $140.14 $206.70 $273.25 66
EV/Revenue $36.93 $78.26 $119.60 51
Asset-Based
NCAV (Graham) $0.6300 $0.8400 $1.26 54
Growth DCF
Growth DCF $101.67 $184.22 $306.02 76
Rev-Margin DCF $71.07 $137.74 $220.26 70
Economic Profit
ROIC Compounder $43.26 $55.68 $66.54 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 62
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 90
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 86
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $52.1M and none bought.

  • SaleJames C FosterDirector4× since Jun 29, 2026: 161,336 shares, avg. $268.13$43.3MOct 22, 202610b5-1 plan
  • SaleShannon M ParisottoCEVP, Disc & Safety Assessment5× since Aug 5, 2026: 13,936 shares, avg. $287.79$4.0MOct 21, 202610b5-1 plan
  • SaleNancy C AndrewsDirector573 shares at $285.24$163,443Aug 18, 2026
  • SaleBirgit GirshickChief Executive Officer, Director6,500 shares at $279.90$1.8MAug 11, 202610b5-1 plan
  • SaleVictoria L CreamerEVP & Chief People Officer4,179 shares at $259.16$1.1MAug 6, 2026
  • SaleMichael Gunnar KnellSVP, Finance and CAO6,645 shares at $260.38$1.7MAug 6, 2026
  • BuyJoseph W LaPlumeEVP, Corp Strategy & Develop25 shares at $174.54$4,364Mar 3, 2026
  • Plan buyGlenn ColemanEVP & Chief Financial Officer10 shares at $297.43$2,974Sep 30, 2026

Plus 43 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +11.4% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.8% (2020) → 12.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.9% a year for the price and −0.9% for the forecasts.
Forecast 2026 (sales)−2.5%
Forecast 2027 (sales)+2.6%
Projected 2028 (sales)+2.5%
Projected 2029 (sales)+2.4%
Projected 2030 (sales)+2.3%

CRL screens overvalued: fair value 61% below the price. Compare with Thermo Fisher Scientific Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Strong operating cash flow is offset by ongoing margin pressure and goodwill impairment, leaving only limited durable advantage in a competitive field.
Main risk: Uneven client spending in research services risks keeping the new digital systems from lifting margins and leaves results volatile.
Bull case: By expanding its Alternative Methods Advancement Project and virtual control groups Charles River could capture recurring revenue from clients seeking regulatory-grade non-animal data and strengthen its position in evolving safety assessment.
Bear case: If regulatory and client preferences shift rapidly toward validated alternatives while NHP sourcing remains constrained the company could see sustained volume declines in core preclinical services and slower adaptation of its service mix.
Charles River is deploying a new digital system to link and automate lab execution across its biologics testing sites in North America and Europe. The move targets manual processes that slow quality control and create error risks in GMP environments. Will this digitization meaningfully lift margins in its research services or mainly help stabilize results amid uneven client spending?
Join the discussion →

Compare Charles River Laboratories with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 60 · Above median
Fair Value upside −61.5% · Below median
Profitability
Return on equity (12 months) 1.3% · Below median
Return on assets −2.0% · Below median
Net margin (12 months) 1.0% · Below median
Operating margin (12 months) 20.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −2.2% · Below median
Balance sheet
Debt / equity 0.67× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 340.2× · Priciest 25%
P/B 4.80× · Pricier than median
P/S (12 months) 3.82× · Pricier than median
Price / free cash flow (fiscal year) 29.3× · Pricier than median
EV/EBITDA 19.1× · Pricier than median
PEG 0.12× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 38
PAST (return on equity)5 · sector 15
HEALTH (low debt)67 · sector 95
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $208.00 $228.80 +10% vs CRL
IQVIA Holdings IQV $264.88 $288.85 +9% vs CRL
WuXi AppTec Co 603259 ¥154.46 ¥164.66 +7% vs CRL
Thermo Fisher Scientific Inc TMO $676.94 $686.04 +1% vs CRL
Danaher Corporation DHR $226.34 $209.18 −8% vs CRL
IDEXX Laboratories, Inc IDXX $670.71 $496.48 −26% vs CRL
Mettler-Toledo International Inc MTD $1,679 $650.28 −61% vs CRL
Agilent Technologies, Inc A $171.78 $64.53 −62% vs CRL
Lonza Group LONN CHF 672.40 CHF 153.50 −77% vs CRL
Waters Corporation WAT $453.08 $91.26 −80% vs CRL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Charles River Laboratories: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Charles River Laboratories Fair Value". https://www.fairvalue-calculator.com/stock/CRL

Frequently asked questions

Is Charles River Laboratories (CRL) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $120.66 versus a price of $313.02, about 61% lower (overvalued).
What is the fair value of CRL?
Our model-based fair value for Charles River Laboratories is $120.66 (as of Nov 6, 2026), built from audited fundamentals. The current price: $313.02.
What is the quality score of CRL?
Charles River Laboratories has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Charles River Laboratories (CRL)?
Our model-based price target is the fair value of $120.66 (as of Nov 6, 2026) from 14 valuation models. Cautious scenario $75.61, optimistic scenario $165.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Charles River Laboratories stock forecast for 2026?
Our models put fair value at $120.66, about 61% lower versus a price of $313.02 (overvalued). Cautious scenario $75.61, optimistic scenario $165.70. The calculation is refreshed regularly with new filings.
What is the revenue of Charles River Laboratories (CRL)?
Charles River Laboratories reported trailing-twelve-month revenue of about $4.0B (latest available figure, as of Nov 6, 2026).
What growth is priced into Charles River Laboratories (CRL)?
For today's price to be fair in a discounted-cash-flow model, Charles River Laboratories would have to grow free cash flow by +19.7 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CRL use?
Our models discount Charles River Laboratories at 10.0 %: a base by market capitalisation (large), damped by beta 1.34, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Charles River Laboratories that is +19.7 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Charles River Laboratories (CRL) delivered so far?
Over the past 5 years revenue at Charles River Laboratories grew +6.6 % a year. The price currently implies +19.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Charles River Laboratories (CRL) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Charles River Laboratories (+19.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Charles River Laboratories (CRL)?
The free-cash-flow yield on the price is 3.42 %: that much free cash flow Charles River Laboratories produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Charles River Laboratories (CRL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Charles River Laboratories it is $120.66 per share (as of Nov 6, 2026), against a price of $313.02. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Charles River Laboratories stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CRL trades above its calculated fair value: price $313.02, fair value $120.66, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRL?
No. The price is what the market pays today ($313.02); the fair value is what the company's own numbers justify ($120.66). For Charles River Laboratories the two are $192.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Charles River Laboratories worth?
The market values Charles River Laboratories at about $15.2B (market capitalisation, as of Nov 6, 2026). Per share that is $313.02; our models calculate a fair value of $120.66 per share.
What do the bullish and bearish scenarios say about CRL?
Our models span a range for Charles River Laboratories: cautious scenario $75.61, base $120.66, optimistic $165.70 per share (as of Nov 6, 2026, price $313.02). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CRL?
Charles River Laboratories trades at a price-to-earnings ratio of 340.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $120.66 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2024), reported earnings: 30.1. Other multiples: PEG 0.1, P/B 4.8, P/S 3.8, EV/EBITDA 19.1.
What is the PEG ratio of CRL?
The PEG ratio of Charles River Laboratories is 0.12 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Charles River Laboratories (CRL)?
Balance-sheet figures for Charles River Laboratories (as of Nov 6, 2026): return on equity 1.3%, debt of 0.67 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is CRL from its 52-week high?
Charles River Laboratories trades at $313.02, about 17% below its 52-week high of $376.10 and 109% above the low of $149.93 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $120.66 is for.
Which stocks are comparable to Charles River Laboratories?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Charles River Laboratories stock attractive at the current price?
The data as of Nov 6, 2026: price $313.02, calculated fair value $120.66 (−61%), Quality Score 60/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRL calculated?
We run Charles River Laboratories through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $120.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Charles River Laboratories itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Charles River Laboratories (CRL)?
The closing price on Nov 5, 2026 was $313.02. Our model-based fair value is $120.66, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Charles River Laboratories right now?
The price sits above even our optimistic bull case ($165.70). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($75.61 to $165.70) leaves room in how you read the outcome.
Where does the earnings growth of Charles River Laboratories (CRL) come from?
Earnings per share at Charles River Laboratories grew +5.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.0 %, EBIT margin −3.8 %, tax rate +0.2 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Charles River Laboratories

How large is the market capitalisation of Charles River Laboratories (CRL)?
The market capitalisation of Charles River Laboratories is $15.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Charles River Laboratories (CRL)?
The price-to-sales ratio of Charles River Laboratories is 3.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Charles River Laboratories (CRL)?
Earnings per share at Charles River Laboratories are $0.9200 (price ÷ EPS = P/E 340.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Charles River Laboratories (CRL)?
The net margin of Charles River Laboratories is 1.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Charles River Laboratories (CRL)?
The return on equity (ROE) of Charles River Laboratories is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Charles River Laboratories (CRL)?
On an EBIT basis the return on assets of Charles River Laboratories is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Charles River Laboratories (CRL)?
The operating margin of Charles River Laboratories is 20.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Charles River Laboratories (CRL)?
Revenue at Charles River Laboratories is growing −2.2% versus a year earlier (3y avg +0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Charles River Laboratories (CRL)?
Earnings per share at Charles River Laboratories are growing +524% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Charles River Laboratories (CRL) carry?
The net debt of Charles River Laboratories is $2.9B (fiscal year 2025, ≈ 5.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Charles River Laboratories in the live analysis

One click puts Charles River Laboratories on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.